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Purpose: During retinal development, post-mitotic neural progenitor cells must activate thousands of genes to complete
synaptogenesis and terminal maturation. While many of these genes are known, others remain beyond the sensitivity of
expression microarray analysis. Some of these elusive gene activation events can be detected by mapping changes in RNA
polymerase-II (Pol-II) association around transcription start sites.
Methods: High-resolution (35 bp) chromatin immunoprecipitation (ChIP)-on-chip was used to map changes in Pol-II
binding surrounding 26,000 gene transcription start sites during photoreceptor maturation of the mouse neural retina,
comparing postnatal age 25 (P25) to P2. Coverage was 10–12 kb per transcription start site, including 2.5 kb downstream.
Pol-II-active regions were mapped to the mouse genomic DNA sequence by using computational methods (Tiling Analysis
Software-TAS program), and the ratio of maximum Pol-II binding (P25/P2) was calculated for each gene. A validation
set of 36 genes (3%), representing a full range of Pol-II signal ratios (P25/P2), were examined with quantitative ChIP
assays for transcriptionally active Pol-II. Gene expression assays were also performed for 19 genes of the validation set,
again on independent samples. FLT-3 Interacting Zinc-finger-1 (FIZ1), a zinc-finger protein that associates with active
promoter complexes of photoreceptor-specific genes, provided an additional ChIP marker to highlight genes activated in
the mature neural retina. To demonstrate the use of ChIP-on-chip predictions to find novel gene activation events, four
additional genes were selected for quantitative PCR analysis (qRT–PCR analysis); these four genes have human homologs
located in unidentified retinal disease regions: Solute carrier family 25 member 33 (Slc25a33), Lysophosphatidylcholine
acyltransferase 1 (Lpcat1), Coiled-coil domain-containing 126 (Ccdc126), and ADP-ribosylation factor-like 4D (Arl4d).
Results: ChIP-on-chip Pol-II peak signal ratios >1.8 predicted increased amounts of transcribing Pol-II and increased
expression with an estimated 97% accuracy, based on analysis of the validation gene set. Using this threshold ratio, 1,101
genes were predicted to experience increased binding of Pol-II in their promoter regions during terminal maturation of
the neural retina. Over 800 of these gene activations were additional to those previously reported by microarray analysis.
Slc25a33, Lpcat1, Ccdc126, and Arl4d increased expression significantly (p<0.001) during photoreceptor maturation.
Expression of all four genes was diminished in adult retinas lacking rod photoreceptors (Rd1 mice) compared to normal
retinas (90% loss for Ccdc126 and Arl4d). For rhodopsin (Rho), a marker of photoreceptor maturation, two regions of
maximum Pol-II signal corresponded to the upstream rhodopsin enhancer region and the rhodopsin proximal promoter
region.
Conclusions: High-resolution maps of Pol-II binding around transcription start sites were generated for the postnatal
mouse retina; which can predict activation increases for a specific gene of interest. Novel gene activation predictions are
enriched for biologic functions relevant to vision, neural function, and chromatin regulation. Use of the data set to detect
novel activation increases was demonstrated by expression analysis for several genes that have human homologs located
within unidentified retinal disease regions: Slc25a33, Lpcat1, Ccdc126, and Arl4d. Analysis of photoreceptor-deficient
retinas indicated that all four genes are expressed in photoreceptors. Genome-wide maps of Pol-II binding were developed
for visual access in the University of California, Santa Cruz (UCSC) Genome Browser and its eye-centric version
EyeBrowse (National Eye Institute-NEI). Single promoter resolution of Pol-II distribution patterns suggest the Rho
enhancer region and the Rho proximal promoter region become closely associated with the activated gene’s promoter
complex.
Cell-specific  gene  expression  is  required  for  the
specialized functions of an adult tissue. Depending on the
tissue of interest, we may know about hundreds of the relevant
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genes and even several key transcription factors that regulate
their  expression.  Unfortunately,  our  knowledge  is  not
complete regarding the number of genes that must become
active  or  their  identities.  Chromatin  immunoprecipitation
(ChIP)-on-chip  analysis  of  RNA  polymerase-II  (Pol-II)
binding in gene promoters has revealed additional and novel
gene activation changes in cultured cells, including embryonic
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252stem cells and cancer cells [1]. We decided to adapt this
analysis to the neural retina, with the goal of finding additional
genes  that  are  activated  during  terminal  maturation  of
photoreceptors in the mouse.
The mammalian neural retina is an established model to
study both the differentiation and maturation of neurons [2].
Six  major  neuronal  cell  types  and  one  glial  cell  type  are
generated from multipotent progenitors during development.
For this study, we focused on a window of mammalian retinal
development, which occurs between postnatal day 2 and 25
(P2 and P25) in the mouse. This phase starts from a point when
the lineage of most cells is already decided but many genes
expressed in the adult retina are not yet active, including those
required for phototransduction, synaptogenesis, and neuron
function. Several well studied photoreceptor-specific genes,
such as rhodopsin (Rho), are activated during this final phase
of development and also provide excellent internal markers
for a temporal ChIP-on-chip study.
Regulation  of  gene  expression  certainly  involves
transcriptional  initiation  when  DNA-binding  transcription
factors recruit chromatin-regulating (epigenetic) proteins and
the general transcriptional machinery. Gene expression may
also be regulated during transcript elongation or degradation
[3-5]. Guenther et al. used Pol-II ChIP-on-chip of embryonic
stem cells to show that Pol-II is detectable downstream of
promoters that produce detectable transcripts [6]; they also
reported many quiescent gene promoters that were preloaded
with inactive Pol-II. We have previously demonstrated, by
quantitative ChIP, that active Pol-II is present in the Rho
gene’s transcriptional region only once the gene is active in
the maturing neural retina [7,8]. We do not know if preloading
of quiescent gene promoters with Pol-II occurs before their
activation in the adult retina. Pol-II ChIP-on-chip mapping
around transcription start sites would also shed light on this
question.
We  mapped  Pol-II  binding  in  mouse  gene  promoter
regions, comparing P2 and P25 neural retina, using ChIP-on-
chip with a high-resolution (35 bp) mouse promoter tiling
array. Active regions of Pol-II binding were correlated to
specific genes, and the Pol-II peak signal ratio (P25/P2) was
used  to  predict  activation  increases  during  terminal
maturation. Prediction accuracy was established by additional
analyses of 36 genes, including quantitative ChIP (qPCR)
analysis  for  transcribing  Pol-II  downstream  of  the
transcription  start  site  (TSS)  and  gene-expression  assays
(mRNA). In addition to Pol-II, we mapped FLT-3 Interacting
Zinc-finger (FIZ1) recruitment to gene promoter complexes.
While FIZ1 expression is ubiquitous in adult mammals, FIZ1
protein content increases tenfold in postnatal mouse retina
[8]. FIZ1 is a zinc-finger protein that is recruited to several
promoter  complexes  of  photoreceptor  genes,  which  are
expressed during terminal maturation of the neural retina [7,
8]. We used this basic property of FIZ1 as an additional marker
for photoreceptor genes that are particularly activated during
this final portion of development.
Pol-II  ChIP-on-chip  predicted  that  863  genes  would
experience the largest proportion of their activation after the
P2  developmental  time  point.  These  genes  represent  key
biologic  processes,  such  as  gene  regulation,  signal
transduction, chromatin organization, epigenetic regulation,
visual transduction, neural development, ion transport, and
synaptic  transmission.  Many  known  retinal  disease  genes
involved  in  photoreceptor  function  and  the  regulation  of
photoreceptor genes were included. Of these genes 28% also
contained significant FIZ1 active regions. Hundreds of the
activated  genes  detected  by  ChIP-on-chip  were  unique
determinations when compared to two previous expression-
array  studies.  Many  of  the  genes  have  human  homologs
located in mapped regions of unidentified retinal diseases.
In  addition  to  providing  a  global  analysis  for  gene
activation,  the  high-resolution  Pol-II  ChIP-on-chip  data
revealed interactions of regulatory regions within the Rho
promoter. While ChIP-on-chip analysis is most often used on
cell cultures, our results demonstrate that this method can be
applied to a complex neural tissue. Pol-II maps were also
adapted  for  graphical  exploration  and  sharing  using  the
University  of  California,  Santa  Cruz  (UCSC)  Genome
Browser and the eye-centric genome browser at National Eye
Institute/National  Institutes  of  Health  (NEI/NIH;
EyeBrowse).
METHODS
Animal care and use: All animal care and tissue collections
performed in this study were performed with the approval of
Oakland  University’s  Animal  Care  and  Use  Committee
(Rochester, MI), and conformed to the USA Department of
Agriculture standards and to the Association for Research in
Vision and Ophthalmology statement for the use of animals
in ophthalmic and vision research. C57BL/6 and Rd1 mice
were obtained from Charles River Laboratories (Wilmington,
MA) and housed at Oakland University in a facility approved
by  the  Association  for  Assessment  and  Accreditation  of
Laboratory Animal Care International.
Tissue isolation and chromatin cross-linking: C57BL/6 mice
were the source for normal neural retina at P2 and P25 and
were processed as previously described for ChIP PCR [7].
Older mice (P25, P33) were sacrificed using a CO2 chamber,
and P2 mice by cervical dislocation. Retinas were dissected
from eyes in PBS (137 mM NaCl, 97 mM Na2HPO4, 25 mM
NaH2PO4,  26  mM  KCl,  Fisher  Scientific,  Pittsburg,  PA),
drained of excess PBS, and fast frozen on dry ice. For both P2
and P25 ages, the retinas were dissected working under a
stereo dissection microscope to ensure tissues were free of
optic nerve, retinal pigment epithelium, and the ciliary body.
Care was also taken to remove any remnants of the tunica
vasculosa lentis from P2 neural retinas. To obtain sufficient
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253chromatin for ChIP-on-chip, 46 retinas were pooled for P2
and 60 retinas were pooled for P25. More tissue was required
with P25 retinas, which yield less chromatin than P2 retinas.
Frozen neural retina tissue was kept at −80 °C until protein/
chromatin cross-linking with freshly prepared formaldehyde
(1% w/v, Sigma Chemicals, St. Louis, MO) for 15 min at room
temperature, with agitation. Cross-linking was stopped by
addition of 0.125 M glycine (final concentration), and tissue
was disrupted with a Dounce homogenizer. Lysates were then
sonicated and the DNA sheared to an average length of 300–
500  bp.  Genomic  DNA  (input)  was  prepared  by  treating
aliquots of chromatin with RNase, proteinase K, and heat
(65  °C)  to  reverse  cross-linking,  followed  by  phenol  and
chloroform extractions and ethanol precipitation. Pellets were
resuspended in 10 mM Tris, 1 mM EDTA, and the resulting
DNA  was  quantified  on  a  Nanodrop  spectrophotometer
(Thermo Fisher Scientific, Chicago, IL). Results were used to
calculate the total chromatin yield.
Chromatin  Immunoprecipitation:  For  ChIP,  an  aliquot  of
chromatin (20 µg) was precleared with protein-A agarose
beads (Invitrogen, Carlsbad, CA). Pol-II binding was detected
using an antibody qualified for ChIP (sc-9001, Santa Cruz
Biotechnology, Santa Cruz, CA). FIZ1 was detected using a
polyclonal antibody specific for the FIZ1 protein, anti-GST-
bFIZ1  (Proteintech  Group  Inc.,  Chicago,  IL),  which  was
previously qualified for quantitative ChIP analysis [7]. After
incubation at 4 °C overnight, protein-A beads were used to
isolate  the  immune  complexes.  Complexes  were  washed,
eluted from the beads with sodium dodecyl sulfate (SDS)
wash  buffer,  and  subjected  to  RNase  and  proteinase-K
treatment. Cross-links were reversed by incubation overnight
at 65 °C, and ChIP DNA was purified by phenol-chloroform
extraction and ethanol precipitation. To confirm enrichment
before  amplification,  qPCR  reactions  were  performed  in
triplicate on specific genome test regions by using SYBR
Green  Super  mix  (Bio-Rad,  Hercules,  CA).  Positive  and
negative  control  regions  were  the  Rho  promoter  and  an
untranslated region on chromosome 6 (Untr6), respectively
[7]. The Untr6 region is 3 Mb downstream of the Rho gene.
Probe preparation and promoter tiling array hybridization:
DNAs were amplified using random priming amplification. A
fixed sequence of 17 bases containing nine random bases at
the 3′ end was used in four linear amplification reactions using
Sequenase (USB, Cleveland, OH). Following purification the
randomly primed ChIP DNA was amplified for 30 cycles
using a fixed primer sequence. The resulting amplified DNA
was purified, quantified, and tested by qPCR again to test for
conservation of enrichment. Amplified DNA was fragmented
and  fluorolabeled  using  the  DNA  Terminal  Labeling  Kit
(Affymetrix,  Santa  Clara,  CA).  Biotinylated  probe  DNA
(1µg) was hybridized to GeneChip Mouse Promoter 1.0R
arrays (Affymetrix) overnight at 45 °C. A single array was
used for each time point with Pol-II, and a third array was
hybridized  with  non-ChIP  total  genomic  DNA  for
normalization. A fourth array was used for FIZ1 ChIP DNA
at  P25.  Arrays  were  hybridized,  washed  and  stained,
simultaneously in a GeneChip Fluidics Station (Affymetrix).
Array scanning and data calculations with Tiling Analysis
Software  (TAS):  Arrays  were  scanned  with  a  GeneChip
scanner (Affymetrix), and array data files were analyzed using
Affymetrix TAS. Array raw input data were normalized using
linear scaling to a target intensity (median intensity) of 500,
using all perfect matched probes. Two sample analyses were
used, with each time point ChIP sample (treatment) compared
to the whole genomic chromatin (control). The tail type was
one-sided  upper  with  a  bandwidth  of  400  bp.  With  the
Affymetrix promoter tiling array (probe spacing 35 bp), a
suitable bandwidth is 0.5 of the average chromatin fragment
size (800 bp) to provide a balance between signal certainty
and mapping resolution. (On average this resulted in 22 probes
per analysis window for each feature of the array. Higher
bandwidths  decrease  signal  p  values  at  the  expense  of
resolution, while lower bandwidths increase resolution at the
expense of certainty.) The Wilcoxon signed rank test was
applied to log-transformed intensities of the ChIP treatment
sample versus the control values for all probes within the
analysis window for each feature in the array. Fold enrichment
was calculated using the Hodges-Lehmann Estimator (pseudo
median) applied to the signal log ratio (log2) between the
treatment  and  control  signal.  Using  these  ratios,  Walsh
averages were calculated for each feature in the array, and a
final probe signal value was calculated as the median Walsh
average. Signal values were exported in bar-file format for
interval determination with TAS and visual inspection with
Integrated  Genome  Browser  software  (IGB,  Affymetrix).
TAS  was  also  used  to  determine  track  intervals.  The
parameters for track interval determination were: minimum
length 300, gap 180, and intermediate thresholds of 2.5 for
FIZ1 and 4.0 for Pol-II. TAS and IGB software are available
for download from the Affymetrix website. GeneChip array
intensity data files (.cel files) and interval track data files (.bed
files) were deposited in the Gene Expression Omnibus (GEO)
database (GEO accession: GSE19999).
Determination  of  gene  associations  and  calculation  of
prediction metrics: To associate interval regions relative to
genes (upstream, in gene, downstream), the track interval
results (.bed format) were processed through the TransPath
program (Genpathway Inc., San Diego, CA), with upstream
and downstream margins from gene ends set to 10 kb.
Post  inspection  of  the  ChIP-on-chip  data  at  internal
markers of terminal maturation or any genes of interest was
accomplished  with  the  IGB  program.  Rho  and  Pde6b
(Phosphodiesterase-6b) provided internal controls as genes
previously shown to be inactive at P2 and active at P25 [8,9].
The TransPath program was used to correlate active regions
with specific genes and then calculate metrics, such as the Pol-
II peak signal ratio (P25/P2). This process is illustrated in
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254Figure  1  for  Pde6b.  Pde6b  (chromosome  5)  encodes
phosphodiesterase-6b,  a  rod-specific  subunit  of
phosphodiesterase  that  is  part  of  the  phototransduction
pathway.  Mutations  of  human  PDE6B  cause  retinal
degeneration through the gradual loss of rod photoreceptors
[10].
Interval  tracks,  determined  with  TAS,  correspond  to
regions with a probe signal above an intermediate threshold,
as described in the previous section. Interval tracks were then
processed using the TransPath program to determine Pol-II
active regions. Active regions were defined by one or more
interval tracks depending on their proximity, as seen in Figure
1A. Tracks less than 5 kb apart were grouped into a single
Figure 1. Determination of Pol-II active-region/gene associations and changes to gene activation state for specific genes. RNA-Polymerase-
II (Pol-II) ChIP-on-chip data could be examined on any continuous scale from entire chromosomes to single genes. Determination of Pol-II
active regions, the association of active regions to genes, and the calculation of specific metrics for each region, required the sequential use
of TAS and the TransPath program. A: First, TAS generated interval tracks where Pol-II signal levels were above an intermediate threshold.
This is illustrated for a region surrounding Pde6B, a key marker of photoreceptor terminal maturation. Second, interval track data were
processed using TransPath to determine active regions. Active regions were comprised of one or more interval tracks in close proximity. Two
active regions are illustrated in the P25 neural retina. B: Higher resolution view of the active region surrounding the Pde6b TSS. Signals for
individual tiling probes (35 bp spacing) are visible. For each active region, TransPath calculated specific metrics, such as the Pol-II peak signal
ratio (P25/P2), as illustrated by the vertical black bars indicating signal maxima from the P25 and P2 time point samples. Genes in view:
Phosophodiesterase 6b (Pde6b), Polycomb group ring-finger 3 (Pcgf3), Complexin 1 (Cplx1).
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255active region. The Pol-II active region spanning the Pde6b
TSS and exon-1 is also shown at a higher resolution in Figure
1B. Gap regions corresponded to repetitive DNA sequences
that were excluded during analysis in TAS, as determined
using the Repeat Masker database (which can be viewed in
the Genome Browser). Metrics calculated with the TransPath
program included the Pol-II peak signal ratio (P25/P2), as
illustrated  in  Figure  1B.  The  Pol-II  peak  signal  ratio  for
Pde6b was 5.0, predicting an increased association of Pol-II
in the mature neural tissue (P25). Coverage on the tiling array
extended several thousand bases downstream of the TSS. We
have previously demonstrated with ChIP that transcribing
Pol-II is detectable deep within the active Rho gene [7].
Quantitative ChIP assays of RNA-Polymerase-II and FLT-3
interacting  zinc  finger-1  binding:  A  multitude  of
photoreceptor genes, known to increase expression from P2
to P25 (i.e., Rho, Pde6b), provided numerous internal controls
to establish confidence in the Pol-II ChIP-on-chip predictions.
However,  since  artifacts  may  influence  the  results  during
ChIP, probe labeling, array hybridization, or washing, we
performed quantitative chromatin immunoprecipitation (Q-
ChIP) assays for a subset of 36 genes. A selection of genes
from the ChIP-on-chip data, representing a full range of Pol-
II peak signal ratios (P25/P2), were analyzed by Q-ChIP. Q-
ChIP was performed with P2 (immature) and P25 (mature)
mouse retina. The retina samples used were different from
those  used  for  ChIP-on-chip.  Real-time  PCR  provided  a
quantitative  comparison  of  the  DNA  recovered  (copy
numbers) and thus comparison of the amount of Pol-II or FIZ1
association  at  target  regions  [11-13].  Quantitative  PCR
reactions were performed in triplicate on specific genome test
regions,  using  SYBR  Green  Super  mix  (Bio-Rad).  The
resulting signals were normalized for primer efficiency by
carrying out qPCR for each primer pair, using input DNA.
Test regions included targets in the Rho promoter and an
untranslated  negative  control  region  on  chromosome  6
(Untr6) [7].
Q-ChIP was performed with an antibody to the serine-2-
phosphorylated C-terminal repeat domain (CTD) of RNA-
Polymerase-II  (Pol-II-S2,  AbCam  Inc.,  Cambridge,  MA).
Serine-2  in  the  Pol-II  CTD  is  phosphorylated  in  the
transcriptionally  active  form  of  the  enzyme  [14,15].
Furthermore, for most genes the target amplicons (about 100
bp) for the Pol-II-S2 Q-ChIP assays were situated downstream
of the TSS. FIZ1 Q-ChIP was also performed with anti-bFIZ1
antibody, which is specific for FIZ1 protein in immunoblots
of  mouse  retina  and  previously  qualified  for  ChIP  [7].
Amplicons for FIZ1 Q-ChIP were targeted to regions of peak
FIZ1 signal, as predicted from ChIP-on-chip. Amplicons were
also placed to avoid repetitive DNA sequences, as determined
from mouse genomic data [16], and visualized in the Repeat
Masker database with the UCSC Genome Browser.
Threshold cycle number (Ct) values from triplicate real-
time PCR assays were transformed using a standard curve of
genomic  DNA  with  known  copy  numbers  to  obtain
precipitated  copy  numbers  for  each  gene  test  region.  To
determine the relative PCR efficiency between different gene
regions,  triplicate  assays  were  run  using  nonprecipitated
genomic DNA (input). Copy numbers of DNA detected were
then  normalized  for  the  amount  of  chromatin  input,  the
proportion  of  ChIP  DNA  used  for  Q-PCR,  and  then  for
relative primer efficiency. Final results were scaled as copies
of DNA detected per 1,000 genome equivalents of input DNA.
Gene expression assays—real-time PCR: Specific genes from
the ChIP-on-chip data representing a full range of Pol-II peak
signal ratios (P25/P2) were analyzed by real-time PCR, using
Taqman  probe  chemistry  following  the  manufacturer’s
standard protocol (Applied Biosystems, Foster City, CA). Pre-
inventoried  assays  were  selected  for  most  genes  with
hydrolysis probes (Taqman probes) spanning an exon splice
junction. Total RNA was isolated from retinal tissues, using
the Absolute RNA Miniprep Kit, and cDNA was synthesized
with the AffinityScript qPCR cDNA Synthesis Kit (both from
Stratagene-Agilent Technologies, La Jolla, CA)
RESULTS AND DISCUSSION
In this study, mouse neural retina at ages P2 and P25 were
analyzed by Pol-II ChIP-on-chip with the Affymetrix Mouse
Promoter 1.0R Array. This permitted us to examine the global
question: how many genes experience significant activation
increases  during  the  terminal  maturation  of  post-mitotic
neural progenitors? Most neural progenitor cells in the retina
have a fixed cell type by P2. However, this stage is also before
the expression of many genes required for actual function of
the neural retina. Excellent markers representing this group of
genes include phototransduction genes, such as Rhodopsin
(Rho) and Phosphodiesterase-6b (Pde6b). The P2 and P25
ages capture the integration of these neural progenitors into a
complex  neurosensory  tissue.  Genes  required  for
photoreceptor and neuron functions are expected to undergo
activation during this interval. These should include genes
required  for  synaptogenesis,  synaptic  function,  and  ion
channels required for neural transmission [17,18].
While the amounts of chromatin required for ChIP-on-
chip  required  large  numbers  of  whole  neural  retinas,  we
expected the data set to be mostly sensitive to photoreceptor-
derived chromatin as these cells represent about 70% of the
mature  neural  retina.  Activation  increases  in  rod-specific
genes or synaptic regulatory genes shared with retinal neurons
were  captured  in  this  analysis.  Gene  activation  increases
specific to cones, Müller cells, ganglion cells, and bipolar cells
were not captured in our Pol-II ChIP-on-chip analysis based
on cell-specific markers for those cells: S-Opsin (Opn1sw),
M-Opsin (Opn1mw) for cones, Glutamine synthetase (Glu1)
for  Müller  cells,  Glial  fibrillary  acidic  protein  (Gfap)  for
ganglion cells, and Protein kinase-C alpha (Prkca) for bipolar
cells [19,20]. Pol-II signal levels for most of those non-rod
genes  remained  below  threshold  at  both  the  P2  and  P25
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256analysis points. Prkca was just above threshold at P25 but its
Pol-II peak signal ratio (P25/P2) was less than 1.8 and was not
predicted to experience significant increased activity. Since
we  are  particularly  interested  in  photoreceptors,  these
properties  were  useful  to  predict  novel  gene  activation
increases, reducing the resources spent on the pursuit of false
positives. Furthermore, we have generated data in a format to
share through the genome browsers at UCSC and the National
Eye Institute (NEIBank). Instructions for viewing these data
are  available  in  the  associated  supplemental  information
Appendix 1.
A substantial percentage of all genes are activated during
photoreceptor maturation: After processing with TAS and
TransPath, the combined P2 and P25 Pol-II ChIP-on-chip data
generated a total of 5,037 Pol-II active regions in the mouse
neural retina. Of this total, 2,427 active regions were exclusive
to the P25 sample. This result suggested that a substantial
number  of  genes  experienced  increased  activation  during
terminal differentiation of the neural retina.
Many key genes required for vision, synaptogenesis, and
neuron function were captured in this gene set. That fact
satisfied  the  key  criterion  for  successful  genome-wide
analysis: the enrichment for genes with biologic functions
relevant to the model of interest [21-23]. We did not find any
of these genes preloaded with Pol-II, as were reported for
embryonic stem cells [6], indicating that a major regulatory
step for their activation was the recruitment of Pol-II itself.
Activated  genes  displayed  Pol-II  active  regions  spanning
downstream of their TSS, as illustrated for Pde6b (Figure 1B).
Validation  of  temporal  RNA-Polymerase-II  ChIP-on-
chip data for predicting increased gene activation state: TAS
was used to analyze promoter array data and to calculate Pol-
II enrichment signals for all tiling probes, using the linear
scaling option. Linear-scaled data were then processed using
the  TransPath  program  to  calculate  additional  metrics,
including the Pol-II peak signal ratio (P25/P2) for each active
Pol-II region. Our aim was to determine a minimal Pol-II peak
signal ratio (P25/P2) to accurately predict gene activation
increases.
A  set  of  genes  with  active  regions  was  selected  to
represent a full range of Pol-II peak signal ratios (P25/P2)
derived from the ChIP-on-chip data set (0.5–14). These genes
and their Pol-II peak signal ratios are listed in Table 1. Several
phototransduction and retinal disease genes were included in
this gene set, and additional analysis was performed by Q-
ChIP assays, using a second antibody with preference for the
actively transcribing form of Pol-II (serine-2 phosphorylated)
(see Figure 2). Pol-II Q-ChIP assays also targeted sites deep
within the transcribed regions of most of these genes to ensure
detection of transcribing Pol-II. Out of 36 genes analyzed by
Q-ChIP, most agreed with the predicted changes in Pol-II
association, as derived from the ChIP-on-chip analysis; an
exception  was  G430022H21Rik  and  Nuclear  receptor
subfamily 1 group D member 1 (Nr1d1).
For  further  evaluation,  gene  expression  assays  were
completed for 19 genes from the validation gene set, which
also represented a full range of Pol-II peak signal ratios. These
results are graphed in Figure 3. All of the test genes with Pol-
II peak signal ratios >1.8 showed increased expression at P25
based upon neural retina mRNA concentration. Based on the
Pol-II Q-ChIP and gene expression results, we concluded that
a ChIP-on-chip Pol-II peak signal ratio (P25/P2) ≥1.8 predicts
significant increases in the gene activation state with >97%
accuracy.  This  ratio  was  used  for  subsequent  prediction
analysis from the full Pol-II ChIP-on-chip data set.
Functional  analysis  of  genes  that  increase  activation
during photoreceptor maturation: From the Pol-II ChIP-on-
chip data, we determined that 1,101 genes (active regions) are
predicted to increase activity during terminal maturation of
the neural retina, based upon a promoter Pol-II peak signal
ratio (P25/P2) ≥1.8. This included genes with or without Pol-
II detected above background at the P2 time point. Figure 4
provides a visual illustration of this prediction metric using
the  ChIP-on-chip  Pol-II  data  for  mouse  chromosome  6.
Several of the genes displaying Pol-II peak signal ratios (>1.8)
are  indicated,  including  Rho,  Transducin  gamma  chain
(Gngt1),  aquaporin  water  channel  (Aqp1),  and  Na+/Cl--
dependent taurine and β-alanine transporter (Slc6a6).
Database for Annotation, Visualization and Integrated
Discovery (DAVID) annotations were available for 81% of
these  genes  (892),  and  these  genes  were  analyzed  for
enrichment according to their gene ontology classifications
for  biologic  processes  (GOTERM_BP_ALL  database;
National  Institute  of  Allergy  and  Infectious  Diseases
[NIAID])  [21,24].  There  was  significant  enrichment  for
biologic  processes  relevant  to  this  model  of  neural
development, including vision, regulation of transcription,
gene expression, neural development/synaptogenesis, neural
function, regulation of chromatin, and ion transport. Vision-
related  genes  (55  genes,  6%)  included  many  that  encode
proteins involved directly in visual transduction and the visual
cycle, such as S-antigen/arrestin (Sag), retinol-binding protein
3, interstitial (Rbp3), phosducin (Pdc), ATP-binding cassette
A-4 (Abca4), recoverin (Rcvn), guanine nucleotide-binding
protein,  α-transducin  1  (Gnat1),  retinol  dehydrogenase  8
(Rdh8), retinitis pigmentosa 1 homolog (Rph1), Pde6b, and
Rho.
A larger proportion of the genes (157 genes, 18%) have
functional  annotations  involving  the  regulation  of  gene
expression.  These  included  the  photoreceptor-specific
transcription factor neural retina leucine zipper (Nrl) and other
transcription factors, including basic helix loop helix b2 and
b3 (Bhlhb2 and 3), calmodulin-binding transcription activator
1 (Camta2), death effector domain-containing DNA-binding
protein 2 (Dedd2), D4, zinc and double Phd fingers family 2
and 3 (Dpf2 and Dpf3), eyes absent 3 homolog, Drosophila
(Eya3), Forkhead box O3A (Foxo3a), Kruppel-like factor 9
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257(Klf9), myocyte enhancer factor 2d (Mef2d), nuclear receptor
subfamily 1d1, 1d2, and 4a3 (Nr1d1, Nr1d2, and Nr4a3), and
prospero-related  homeobox  1  (Prox1).  The  percentage  of
these genes reported to express in the brain, eye, and retina
are 31%, 16%, and 10% respectively.
Functional and tissue enrichment analyses suggested that
Pol-II ChIP-on-chip can predict gene activation increases that
are functionally relevant to the mature neural retina. This was
confirmed by the presence of a substantial number of genes
(32) with human homologs that are currently linked to retinal
diseases:  ATP-binding  cassette  sub-family  A  member  4
(Abca4), Aryl hydrocarbon receptor interacting protein-like 1
(Aipl1),  Bardet-Biedl  syndrome  4  (Bbs4),  Bardet-Biedl
syndrome  7  (Bbs7),  Calcium  binding  protein-4  (Cabp4),
Calcium  channel  voltage-dependent  alpha1F  subunit
(Cacna1f), Elongation of very long chain fatty acids like 4
TABLE 1. GENES USED FOR VALIDATION OF CHIP-ON-CHIP PREDICTIONS.
Number Gene name Chromosome Pol-II peak signal ratio (P25/
P2)
1 Slc24a1 9 14
2 Ablim1 19 11.1
3 Rcvrn 11 10.9
4 Rho 6 10
5 A930008G19Rik (Fam53b) 7 8.5
6 Rs1h X 8
7 Mef2c 13 6.7
8 Grk1 8 6.5
9 Dpf3 12 6.5
10 Rdh12 12 5.7
11 Mllt6 11 5.6
12 Jmjd2c 4 5.6
13 Sag 1 5.2
14 Pde6b 5 5
15 Syne1 10 4.9
16 Cdk5r2 1 4.9
17 Vtn 11 4.4
18 Cckbr 7 4.3
19 Rds 17 4.1
20 Uckl1 2 3.9
21 E130103I17Rik (Bbs9) 9 3.8
22 Slc38a3 9 3.5
23 Gnat1 9 3.5
24 6330407D12Rik (Ccdc126) 6 3.2
25 Ttc8 12 3
26 Rp1h 1 2.9
27 Rbp3 14 2.9
28 Coro2b 9 2.9
29 Nr1d1 11 2.8
30 G430022H21Rik 3 2.2
31 Rab14 2 2.1
32 Elovl4 9 1.8
33 Rheb 5 1.8
34 Hdac10 15 1.7
35 Hdac9 12 1.6
36 Rnf11 4 1.3
37 Grik2 10 0.9
38 Casc5 2 0.5
Genes represent a full range of Pol-II peak signal ratios (P25 / P2). Genes with ratios >1 potentially have increased amounts of
Pol-II binding in mature (P25) versus immature (P2) neural retina.
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258(Elovl4),  Frizzled  homolog  4  (Fzd4),  Guanine  nucleotide
binding  protein,  alpha  transducing  1  (Gnat1),  G  protein-
coupled receptor kinase 1 (Grk1), Guanylate cyclase activator
1A  and  1B  (Guca1a,  Guca1b),  Inosine  monophosphate
dehydrogenase  1  (Impdh1),  Jagged  1  (Jag1),  Potassium
channel  subfamily  V  member  2  (Kcnv2),  Monogenic
audiogenic  seizure  susceptibility  1  (Mass1),
Nephronophthisis  4  (Nphp4),  Nrl,  Pde6a,  Pde6b,
Phosphoglycerate kinase 1 (Pgk1), Retinol dehydrogenase 12
(Rdh12),  Peripherin  2  (Rds),  Regulation  of  G-protein
signaling 9 (Rgs9), Regulator of G protein signaling 9 binding
protein (Rgs9bp), Rho, Retinitis pigmentosa GTPase regulator
Figure 2. Validation of RNA-Polymerase-II (Pol-II) ChIP-on-chip predictions: changes in activated Pol-II association within genes during
terminal maturation of photoreceptors. Q-ChIP assays were performed using an antibody specific for active RNA polymerase-II, which is
phosphorylated at serine-2 of the C-terminal repeat domain (Pol-II-S2). Genes assayed represent a full range of ChIP-on-chip Pol-II peak
signal ratios (P25/P2) from 14 to 0.5 (Table 1). Pol-II binding is proportional to the amount of target DNA captured by ChIP, graphed as
copies of target DNA detected per 1,000 genome equivalents of input genomic DNA. Most assays target in the gene, downstream of the TSS.
Results were normalized for chromatin input and PCR efficiency. Error bars indicate standard deviation (n=3). An untranslated region
(Untr6) on chromosome 6 provided a negative control. The relative position of each PCR target is indicated with the gene symbol. For example,
Slc24a1+1798 indicates the 5′-end of the PCR target was 1,798 bases downstream of the Slc24a1 TSS. Rho, Rcvn, Pde6b, and Sag1 are key
markers of photoreceptor-specific gene expression. Grik2 and Casc5 were included as genes with ChIP-on-chip Pol-II peak signal ratios <1.
Genes: Solute carrier family 24, Na/K/Ca exchanger, member 1 (Slc24a1), Actin binding LIM protein1 (Ablim1), Recoverin (Rcvrn),
Rhodopsin (Rho), Family with sequence similarity 53, member B (A930008G19Rik, Fam53b), Retinoschisis 1 homolog (Rs1h), G protein-
coupled receptor kinase 1 (Grk1), D4, zinc and double PHD fingers, family 3 (Dpf3), Retinol dehydrogenase-12 (Rdh12), Myeloid/lymphoid
or mixed-lineage leukemia 6 (Mllt6), Jumonji domain containing 2C (Jmjd2c), S-antigen (Sag), Phosphodiesterase 6b (Pde6b), Spectrin repeat
containing, nuclear envelope 1 (Syne1), Cyclin-dependent kinase 5, regulatory subunit 2 (Cdk5r2), Vitronectin (Vtn), Cholecystokinin-2
receptor (Cckbr), Peripherin 2 (Rds), Uridine-cytidine kinase 1-like 1 (Uckl1), Bardet-Biedl syndrome 9 (E130103I17Rik, Bbs9), Solute carrier
family 38, Na/H -coupled glutamine transporter, member 3 (Slc38a3), Transducin alpha (Gnat1), Coiled coil domain containing 126
(6330407D12Rik, Ccdc126), Tetratricopeptide repeat domain 8 (Ttc8), Retinitis pigmentosa 1 (Rp1h), Retinol binding protein 3, interstitial
(Rbp3), Coronin, actin binding protein, 2B (Coro2b), Nuclear receptor subfamily 1, group D, member 1 (Nr1d1), G430022H21Rik, RAB14,
member RAS oncogene family (Rab14), Elongation of very long chain fatty acids-like 4 (Elovl4), Ras homolog enriched in brain (Rheb),
Histone deacetylase 10 (Hdac10), Histone deacetylase 9 (Hdac9), Ring finger protein 11 (Rnf11), Glutamate receptor, ionotropic, kainate 2
(beta 2) (Grik2), Cancer susceptibility candidate 5 (Casc5).
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259interacting  protein  1  (Rpgrip1),  S-antigen  (Sag),
Tetratricopeptide repeat domain 8 (Ttc8), Tubby like protein
1 (Tulp1), Unc119 homolog (Unc119), and Whirlin (Whrn;
Retinal Information Network).
RNA-Polymerase-II  ChIP-on-chip  prediction  of  genes
mostly activated after age P2: The analysis above included all
genes that increase expression from P2 to P25, based upon
their associated Pol-II peak signal ratio (P25/P2), regardless
of their activation state at the P2 developmental time point.
We then focused on genes from the Pol-II ChIP-on-chip data
set that were predicted to experience the largest proportion of
their activation between P2 and P25. Using the TransPath
program we first identified 2,427 genes that were associated
with Pol-II active regions above background at P25 but not at
P2, as illustrated in Figure 1 for Pde6b. These genes were then
filtered for those with Pol-II peak signal ratios (P25/P2) ≥1.8,
yielding  a  final  list  of  863  genes  that  were  predicted  to
experience the bulk of their activation after age P2. The full
list is available in Appendix 2, with each gene’s associated
Pol-II peak signal ratio.
Functional annotations were available for 704 of these
genes in the DAVID gene ontology database (refer to Table
Figure 3. Expression changes (mRNA) of evaluation genes. A-C: Relative mRNA concentrations in the mouse neural retina were measured
by qPCR (real time) for the developmental ages P2 and P25. Concentrations were normalized to the beta-Actin mRNA concentration. Bars
indicate standard deviation for triplicate assays. Taqman chemistry was used for target specificity with hydrolysis probes that span exon
junctions. Rho, Rcvn, Pde6b, and Sag1 are key markers of photoreceptor-specific gene expression. Genes are grouped to account for different
scales of relative expression. Most genes had Pol-II peak signal ratios > 1.8, as determined from temporal Pol-II ChIP-on-Chip analysis, except
for: Hdac9 (ratio 1.6), Hdac10 (ratio 1.7), and Grik2 (ratio 0.9, Table 1). Genes: Rhodopsin (Rho), Recoverin (Rcvrn), Retinoschisis 1
(Rs1), Phosphodiesterase 6b (Pde6b), S-antigen (Sag), Elongation of very long chain fatty acids-like 4 (Elovl4), D4, zinc and double PHD
fingers, family 3 (Dpf3), Spectrin repeat containing, nuclear envelope 1 (Syne1), Solute carrier family 38, Na/H -coupled glutamine transporter,
member 3 (Slc38a3), Family with sequence similarity 53, member B (A930008G19Rik, Fam53b), Nuclear receptor subfamily 1, group D,
member 1 (Nr1d1), Jumonji domain containing 2C (Jmjd2c), Histone deacetylase 9 (Hdac9), Bardet-Biedl syndrome 9 (E130103I17Rik,
Bbs9), Histone deacetylase 10 (Hdac10), Glutamate receptor, ionotropic, kainate 2 (beta 2) (Grik2), Solute carrier family 24, Na/K/Ca
exchanger, member 1 (Slc24a1).
Molecular Vision 2010; 16:252-271 <http://www.molvis.org/molvis/v16/a32> © 2010 Molecular Vision
2602). Eighty-nine of the genes (13%) are involved in visual
function.  Ten  of  these  genes  encode  proteins  of  the
phototransduction  pathway  and  are  known  to  be  mostly
activated  after  P2  in  photoreceptors,  including  Rho,
Phosducin (Pdc), Gnat1, and Recoverin (Rcvrn); 11 genes are
involved in synaptic transmission, including Synapse protein
25 (Snap25), Acetylcholinesterase (Ache), and Solute carrier
family  17,  sodium-dependent  inorganic  phosphate
cotransporter, member 7 (Slc17a7); 110 genes (16%) have
roles in the regulation of gene expression; 106 genes (15%)
are involved in signal transduction; and 15 genes (2%) are
involved in chromosome organization and biogenesis.
FIZ1  recruitment  to  genes  activated  during
photoreceptor maturation: FIZ1 is a zinc-finger protein that
Figure 4. ChIP-on-chip map of changes in RNA-Polymerase-II (Pol-II) association around transcription start sites on chromosome 6 in P2
and P25 mouse neural retina. ChIP was performed using an antibody specific for RNA polymerase-II. ChIP DNA was amplified, labeled, and
hybridized onto Affymetrix gene chip mouse promoter tiling arrays (v.1), as detailed in the methods. Probe intensity data were normalized to
total genomic DNA (non-ChIP) and the linear scaling format option. Chromosome 6 data are shown here for age P2 (Pol-II P2) and age P25
(Pol-II P25), including a plot of the Pol-II signal ratio (P25/P2 ratio). The horizontal line indicates the Pol-II peak signal ratio (1.8) selected
to predict an increased activation state during terminal maturation of photoreceptors. This value was validated through follow-up analysis of
the test gene set representing a full range of Pol-II peak signal ratios (Table 1). The locations of many genes displaying activation increases
are readily visible. Some examples include Rhodopsin (Rho), Transducin-γ subunit (Gngt1), Aquaporin (Aqp1), and Na: neurotransporter
symporter for taurine and β-alanine (Slc6a6).
TABLE 2. POL-II CHIP-ON-CHIP PREDICTION OF GENES EXPERIENCING MOST ACTIVATION AFTER P2.
Function Count Example genes
Vision 89 Sag, Rho, Rpgrip1, Gnat1, Rp1h, Gucy2e
Phototransduction 10 Rcvrn, Guca1a, Rho, Gnat1, Pdc, Pdcl3
Transport 124 Cacna1f, Kcnj9, Kcnv2, Slc25a35, Slc23a3
Regulation of transcription 92 Ahr, Ankrd33, Cyr2, Nr4a3, Pbx3, Eya3
Gene expression 110 Smad4, Dpf3, Jmjd2c, Nr1d2, Rxra
Neuron development 11 Nfasc, Ntng2, Syngap1, Cacna1f
Nervous system development 21 Map2k1, Cln8, Ablim1, Rora, Lrp2
Ion transport 33 Slc38a3, Slc24a1, Clcn3, Kcnj9
Signal transduction 106 Gngt1, Gnb1, Gucy1a3, Rp1h, Grk1
Synaptic transmission 11 Ache, Cln8, Snap25, Gabra1, Epas1
Chromatin modification 9 Jmjd2c, Sap18, Cbx8, Sirt2
Chromatin organization 15 Smarca2, Jmjd2b, Jmjd2c, Jarid1b
CNS development 6 Cln8, Rora, Sept4, Pex5, Top2b, Lrp2
To select for genes predicted to experience most of their activation increase after age P2, the criteria were: Pol-II signal levels
below  background threshold at P2, and Pol-II peak signal ratios (P25/P2) ≥1.8. Functional clustering analysis was performed
using the DAVID gene ontology database. Complete lists of all genes, with their associated Pol-II peak signal ratios (P25/P2),
may be found in Appendix 2.
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261is recruited to the promoter complex of several photoreceptor
genes that become active during terminal maturation of the
neural retina. FIZ1 can interact directly with two transcription
factors,  cone-rod  homeobox  (CRX)  and  NRL,  that  are
required for activating photoreceptor genes [7,8]. While FIZ1
expression  is  ubiquitous  in  adult  mammals,  FIZ1  protein
content increases tenfold during postnatal maturation of the
mouse neural retina [8]. While all of FIZ1’s functions and
interactions remain to be elucidated, the availability of a ChIP-
qualified  antibody  made  it  possible  to  use  FIZ1  as  an
additional  biomarker  for  genes  becoming  activated  in  the
adult retina.
Out of 863 genes predicted to experience most of their
activation after P2, based on Pol-II binding (previous section),
243 genes (28%) scored positive for FIZ1 association at their
promoter regions in adult (P25) neural retina. A full list of
these genes and their locations may be found in Appendix 3.
FIZ1 ChIP-on-chip predictions were confirmed by additional
FIZ1 Q-ChIP assays, using a second antibody for FIZ1 and
the same set of genes analyzed by Pol-II Q-ChIP. FIZ1 Q-
ChIP results for 36 genes at the P2 and P25 developmental
stages confirmed the recruitment of FIZ1 to most of the genes
experiencing  increases  in  Pol-II-Ser2  association  during
terminal maturation (see Figure 5).
Functional clustering analysis was possible for 162 of the
genes that had sufficient annotations in the DAVID database.
These are summarized in Table 3: 20% have roles in vision,
22% in signal transduction, 22% in gene expression, and 26%
Figure 5. Comparison of FLT-3 interacting zinc finger 1 (FIZ1) recruitment to gene promoter complexes during terminal maturation of
photoreceptors. ChIP was performed using an antibody specific for the FIZ1 protein. Protein binding is proportional to the amount of target
DNA captured by ChIP and is shown as copies of target DNA detected per 1,000 genome equivalents of input DNA. Results were normalized
for chromatin input and PCR efficiency. Error bars indicate standard deviation (n=3). An untranslated region (Untr6) on chromosome 6
provided a negative-binding control. The 5′ end location of each PCR target is indicated with each gene name. For Example, Slc24a1-463
indicates that the qPCR target was 463 bases upstream of the Slc24a1 TSS. Rho, Rcvn, Pde6b, and Sag1 are key markers of photoreceptor-
specific gene expression. Grik2 and Casc5 were included as genes with ChIP-on-chip Pol-II peak signal ratios <1.0. Genes: Solute carrier
family 24, Na/K/Ca exchanger, member 1 (Slc24a1), Actin binding LIM protein1 (Ablim1), Recoverin (Rcvrn), Rhodopsin (Rho), Family
with sequence similarity 53, member B (A930008G19Rik, Fam53b), Retinoschisis 1 homolog (Rs1h), G protein-coupled receptor kinase 1
(Grk1), D4, zinc and double PHD fingers, family 3 (Dpf3), Retinol dehydrogenase-12 (Rdh12), Myeloid/lymphoid or mixed-lineage leukemia
6 (Mllt6), jumonji domain containing 2C (Jmjd2c), S-antigen (Sag), Phosphodiesterase 6b (Pde6b), Spectrin repeat containing, nuclear
envelope 1 (Syne1), Cyclin-dependent kinase 5, regulatory subunit 2 (Cdk5r2), Vitronectin (Vtn), Cholecystokinin-2 receptor (Cckbr),
Peripherin 2 (Rds), Uridine-cytidine kinase 1-like 1 (Uckl1), Bardet-Biedl syndrome 9 (E130103I17Rik, Bbs9), Solute carrier family 38, Na/
H -coupled glutamine transporter, member 3 (Slc38a3), Transducin alpha (Gnat1), Coiled coil domain containing 126 (6330407D12Rik,
Ccdc126), Tetratricopeptide repeat domain 8 (Ttc8), Retinitis pigmentosa 1 (Rp1h), Retinol binding protein 3, interstitial (Rbp3), Coronin,
actin binding protein, 2B (Coro2b), Nuclear receptor subfamily 1, group D, member 1 (Nr1d1), G430022H21Rik, RAB14, member RAS
oncogene family (Rab14), Elongation of very long chain fatty acids-like 4 (Elovl4), Ras homolog enriched in brain (Rheb), Histone deacetylase
10 (Hdac10), Histone deacetylase 9 (Hdac9), Ring finger protein 11 (Rnf11), Glutamate receptor, ionotropic, kainate 2 (beta 2) (Grik2), Cancer
susceptibility candidate 5 (Casc5).
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262in transport processes. FIZ1 active areas were associated with
15  currently  known  retinal  disease  genes:  Bbs7,  Bbs9,
Elovl4,  Gnb1,  Gnat1,  Gngt1,  Grk1,  Jag1,  Sag,  Pde6a,
Pde6b, Rho, Rdh12, Rp1h, and Rpgrip1. FIZ1 Q-ChIP assays
for eight of those genes (Bbs9, Elovl4, Gnat1, Grk1, Sag,
Pde6b, Rho, and Rp1h) confirmed an increased association of
FIZ1 at P25 versus P2 (Figure 5). While the precise role of
FIZ1 in the formation of these activation complexes is not
known  at  this  time,  evidence  to  date  suggests  that  FIZ1
recruitment to photoreceptor gene promoters is dependent on
DNA-binding pioneer transcription factors, such as CRX and
NRL [7,8]. Indeed, expression for many of the genes were
reported  in  green  fluorescent  protein  (GFP)-sorted  rod
photoreceptors, and their expression is diminished in NRL(−/
−) mice [25], including Gnat1, Rho, Grk1, Jag1, Pde6b, Gnb1,
Rdh12,  Rd1h,  Sag,  Rcvrn,  Interphotoreceptor  matrix
proteoglycan  1  (Impg1),  WD  repeat  domain  17  (Wdr17),
Nucleoredoxin-like 1 (Nxnl1), Stomatin (Stom), Membrane
protein palmitoylated 4 (Mpp4), and Rho GTPase activating
protein 24 (Arhgap24).
Novel  gene  activations  predicted  by  temporal  RNA-
Polymerase-II  ChIP-on-Chip  analysis:  Expression
microarray  studies  of  mouse  retinal  development  have
revealed hundreds of genes that increase expression during
terminal maturation [26,27]. Those studies revealed important
information  regarding  gene  regulation  during  retinal
development and expanded the list of candidate genes for
numerous retinal diseases. Even so, many gene expression
changes await discovery for two reasons. First, different array
platforms detect many gene expression changes not captured
by the other platform [26]. Second, hybridization of a complex
probe population limits the ability to see changes in the lower
abundance transcripts.
Pol-II ChIP-on-chip examines relative changes in Pol-II
association;  therefore,  it  had  the  potential  to  detect  the
activation of additional genes. Even a few hundred additional
gene activation events would be valuable data to supplement
those already revealed by expression microarrays. To confirm
the potential of Pol-II ChIP-on-chip to find additional genes
activated  during  terminal  maturation  of  the  retina,  we
compared our Pol-II ChIP-on-chip gene activation predictions
(Pol-II peak signal ratio P25/P2≥1.8) with two excellent sets
of published expression microarray data [26,27]. Because of
different  array  platforms  and  differences  in  the  principal
detection method (mRNA versus Pol-II), a substantial number
of gene activation predictions were unique to all three data
sets. From a three-way comparison, 820 activation events
were unique to the Pol-II ChIP-on-chip-predicted data set. The
three gene lists that were compared and the ChIP-on-chip
unique list are available in Appendix 4.
Functions  of  the  ChIP-on-chip  unique  genes  are
summarized in Table 4. A substantial number were associated
with  vision,  including  Guca1b,  Retinol  dehydrogenase-8
(Rdh8),  Guanylate  cyclase  membrane  type-e  (Gucy2e),
Retinal degeneration-3 (Rd3, 3322402L07Rik), Metabotropic
glutamate  receptor-6  (Grm6),  Rdh12,  Bbs4,  Aipl1,  and
Cacna1f.  Aipl1  and  Rdh12  activation  increases  were
previously detected by Akimoto et al. [25] with expression
microarrays,  but  only  after  GFP  sorting  to  isolate  rod
photoreceptors.
Pol-II ChIP-on-chip analysis was particularly sensitive to
detecting increased activation of genes involved in transport
processes  and  ion  transport.  These  included  many  solute
carrier family proteins, such as Slc26a6, Slc41a1, Slc4a10,
and  Slc4a7.  Also  enriched  were  cellular  genes  encoding
subunits of mitochondrial ATPase: Atp1a3, Atp8a1, Atp5d,
Atp5b, and Atp5k. Atp1a3 mutations are associated with rapid
onset  dystonia  parkinsonism  [28].  Disruption  of  Slc4a10
(sodium bicarbonate transporter) was recently associated with
complex partial epilepsy, and mice lacking Slc4a7 develop
degeneration of sensory receptors of the eye and inner ear, as
in  Usher  syndrome  [29].  These  neurosensory  associations
TABLE 3. GENES ACTIVATED IN MATURING NEURAL RETINA THAT RECRUIT FIZ1 TO PROMOTER COMPLEXES.
Function Count Example genes
Vision 32 Rho, Rcvrn, Sag, Pde6b, Rp1h
Phototransduction 5 Rcvrn, Rho, Gnb1, Gnat1, Pdc
Transport 42 Rcvrn, Clcn3, Slc38a3, Kctd7
Regulation of transcription 27 Ahr, Mier1, Pbx3, Rora, Ablim1
Gene expression 36 Jmjd2c, Ahr, Pprc1, Srct1, Klf9
Ion transport 12 Clcn3, Slc38a3, Slc24a1, Kctd7
Neuron development 4 Nfasc, Mtap2, Ablim1, Rtn4
Nervous system development 9 Ipmk, Map2k1, Nfasc, Sep4
Signal transduction 36 Gngt1, Gnb1, Rgs9bp, Pde6b
Synaptic transmission 3 Snap25, Park2, Slc17a7
Chromatin organization 4 Jmjd2c, Ercc1, Nap1l2, Bnip3
Criteria were: Pol-II peak signal ratio (P25/P2) ≥1.8, and FIZ1 peak signal above background threshold. Functional clustering
was performed using the DAVID gene ontology database. A complete list of all genes may be found in Appendix 3.
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263emphasize  that  these  transport  families  are  important  for
functionality and represent a large and additional pool of
genes to explore during maturation of the neural retina.
Novel candidates for genes involved in retinal maturation
and function: From the ChIP-on-chip unique predictions of
genes showing increased activation after P2, ten have human
homologs that are linked to human retinal diseases [30-40]:
AIPL1, BBS4, CACNA1F, RDH12, Retinitis Pigmentosa 1
(RP1),  Glutamate  Receptor,  Metabatropic  6  (GRM6),
GUCA1B,  Retinal  Degeneration  3  (RD3),  and  Ceroid-
Lipofuscinosis,  Neuronal-5  and  −8  (Cln5,  Cln8).  This
demonstrates  that  the  ChIP-on-chip  predictions  should
contain additional genes necessary for normal retinal function.
Some are related to other known visual function genes, and
we suggest they are good candidates for further exploration.
Rdh8 is a member of the retinol dehydrogenase gene family,
and  another  family  member,  RDH12,  is  linked  to  retinal
degenerations. Phosducin-like 3 protein (Pdcl3) and other
members of this gene family (Pdcl1 and 2) appear to be co-
chaperones  with  the  cytoplasmic  chaperonin  complex.
Phosducin itself has a visual role as a chaperone for G protein
β-γ subunits as they are translocated between photoreceptor
outer and inner segments during light adaptation [41].
Approximately 250 of the genes do not have well defined
functions and also represent a potential source of novel genes
required for maturation and function of the neural retina. We
examined the chromosome locations of their human homologs
and found that several are located within the mapped regions
of unidentified retinal diseases (Table 5). SLC25A33 is located
in the region for LCA9 [42] and encodes for a mitochondrial
carrier family member with relatively high expression in the
eye (qPCR) compared to other members of this large gene
family. It is also expressed at relatively higher levels in neural
tissues, including the spinal cord and the cerebellum, while its
expression  in  peripheral  tissues  is  quite  low  [43].
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is one
of three transmembrane LPCAT family members that transfer
fatty acids from acyl-CoA to lysophosphatidylcholine [44].
Human  LPCAT1  is  in  the  mapped  region  for  dominant
macular dystrophy-3 [45]. Several other genes involved in
lipid homeostasis and transport have been linked to retinal
diseases, including dominant cone-rod dystrophy [46] and
recessive abetalipoproteinemia [47].
The CCDC126 gene encodes for a protein of unknown
function:  coiled-coil  domain-containing  126  .  The  human
gene  falls  in  the  mapped  interval  reported  for  autosomal
dominant  cystoid  macular  dystrophy  [48].  ARL4D  (Arf4l)
encodes  for  ADP-ribosylation  factor-like  4D  [49].  ARL
family members are related to the ADP-ribosylation factor
(ARF) family of proteins. ARF proteins have important roles
in intracellular traffic, and the ARL proteins are a guanosine
triphosphates (GTP)-binding protein family. Another member
from this family, ARL6, was identified as the gene for Bardet-
Biedl  syndrome-3  (BBS-3),  a  disorder  that  includes
retinopathy,  learning  disabilities,  obesity,  and  renal  and
cardiac malformations [50].
Follow-up gene expression analysis confirmed that the
expression of all four genes is increased during maturation of
the neural retina (Table 5). Arl4d and Ccdc126 demonstrated
the largest maturation-related expression increases of 26 fold
and 127 fold, respectively. Slc25a33 and Lpcat1 expression
increased 3.5 fold and sevenfold, respectively. The expression
of all four genes was diminished in mature Rd1 mouse neural
TABLE 4. FUNCTIONAL ANNOTATION ANALYSIS (DAVID) OF NOVEL GENE ACTIVATIONS, PREDICTED BY POL-II CHIP-ON-CHIP.
Function Count (%)
Regulation of transcription 90 14
Gene expression 118 18
Visual perception 13 2
System process (vision) 26 4
Transport 92 14
Phototransduction 3 1
Signal transduction 80 12
Nervous system development 18 3
Neuron development 9 1
Synaptic transmission 5 1
Chromosome organization and biogenesis 12 2
Chromatin modification 5 1
Ion transport 17 3
Central nervous system development 5 1
Gene activations predicted by Pol-II ChIP-on-Chip, which are additional to those reported by two previous microarray studies.
The  full list of genes (820) and list comparisons are provided in Appendix 4. Of the 820 genes, 463 had sufficient annotations
for functional clustering, and the results are summarized in this table.
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264retina compared to normal retina. Rd1 neural retinas were
compared  at  age  P33,  and  loss  of  over  99.7%  of  rod
photoreceptors  and  50%  of  cone  photoreceptors  was
confirmed by gene expression analysis of NRL and M-opsin
(data  not  shown).  Relative  expression  of  Slc25a33  and
Lpcat1  was  reduced  by  half  in  Rd1  retinas,  indicating
relatively high expression in photoreceptor neurons. Relative
expression in photoreceptors was much higher for Arl4d and
Ccdc126; their overall retinal expression was diminished by
90% in Rd1 retinas compared to normal retinas.
RNA-Polymerase-II  ChIP-on-chip  analysis  of  the
Rhodopsin promoter: An additional benefit of high-resolution
ChIP-on-chip data are the ability to visualize differences in
Pol-II  association  along  adjacent  portions  of  the  DNA
sequence.  This  geographic  interpretation  can  reveal
mechanistic clues pertaining to specific gene promoters or
alternate promoters. Regions of maximal Pol-II signal can
reveal  promoter  sequences  that  are  brought  into  close
proximity  within  the  DNA/protein  complex  of  the
enhanceosome. Upstream enhancers and the TSS can come
into close proximity through interactions of proteins in the
activating promoter complex, resulting in the formation of
chromatin  loops  [51].  In  cell  culture  estrogen  receptor
activates the CTSD gene with the concomitant formation of a
chromatin  loop,  which  brings  a  distal  upstream  enhancer
region into close proximity to the TSS. As a result, Pol-II maps
by  ChIP  at  both  the  distal  enhancer  and  the  TSS  of  the
activated  Cathepsin  D  (CTSD)  gene  [52].  A  detailed
examination of our Rho Pol-II ChIP-on-chip data suggested
that similar loop mechanisms can also exist in native tissues.
High-resolution plots of Pol-II association for Rho are
presented in Figure 6A. Two Pol-II signal maxima were noted
to correspond to the Rhodopsin proximal promoter region
(RPPR) and the upstream Rhodopsin enhancer region (RER)
[53-57]. Both regions bind nuclear proteins from neural retina
and are involved in the activation and enhancement of Rho
promoter activity. The RPPR is essential for activation by the
transcription factors NRL and CRX [58-60]. Several DNA
sequence elements in this 500-bp region bind transcriptional
proteins in vitro. These include the NRL response element that
is present in several  rod-specific  genes:  RHO, PDE6B,  a-
PDE, and GNAT1 [59-70]. NRL synergistically co-activates
the Rho promoter with CRX, and these two proteins directly
interact [58,66,71]. Several homeobox transcription factors,
Retina and anterior neural fold homeobox−2 (RAX2), Retina
and  anterior  neural  fold  homeobox  (RAX),  and  Cone-rod
homeobox  (CRX),  can  bind  to  the  Ret-1/photoreceptor
conserved element-1 (PCE-1) DNA-sequence element of the
RPPR and also enhance activity of the promoter [67,72,73].
NRL and CRX can directly bind FIZ1. FIZ1 ChIP-on-chip
resulted in a maximum FIZ1 signal corresponding to this
NRL- and CRX-binding region (Figure 6A).
While the RPPR is sufficient for activation, maximal
expression of the rhodopsin gene requires the RER, which is
a conserved region (about 100 bp) found 1.5–2 kb upstream
of  the  TSS,  depending  on  the  species  [63].  The  bimodal
distribution of Pol-II association at the Rho promoter suggests
the formation of an activating chromatin loop between the
RER and RPPR regions in vivo. (Figure 6B)
Conclusions:  We  have  analyzed  the  activation  of
thousands of genes during terminal maturation of a neural
tissue using ChIP-on-chip to map Pol-II association around
TSSs. Relative increases in Pol-II binding could accurately
predict genes activated during maturation of photoreceptors
in the retina. Pol-II ChIP-on-chip detected the activation of
several  hundred  genes  in  addition  to  those  known  from
previous expression microarrays analysis. These represent a
substantial and novel source of candidate genes that support
TABLE 5. SOME EXAMPLES OF GENE ACTIVATION INCREASES PREDICTED BY POL-II CHIP-ON-CHIP, WHICH HAVE HUMAN HOMOLOGS LOCATED IN MAPPED INTERVALS OF UNIDENTIFIED
RETINAL DISEASES.
mRNA expression P2 versus
   P25 mouse neural retina
              (±SD, n=3)
mRNA expression normal versus
       Rd1 mouse neural retina






homolog (P25/P2) P2 P25 Normal (P33) Rd1 (P33)
LCA9(1p36) SLC25A33 2 1.00±0.07 7.1±0.1† 1.00±0.06 0.49±0.01†
MCDR3(5p15.33-p13.1) LPCAT1 2.2 1.00±0.03 3.5±0.4† 1.00±0.01 0.55±0.05†
MDDC, CYMD (7p21-p15) CCDC126 3.2 1.0±0.1 26.1±0.2† 1.00±0.04 0.09±0.03†
CORD4(17q) ‡ ARL4D 3.6 1.0±0.2 127±11† 1.00±0.04 0.12±0.01†
Pol-II peak signal ratios (P25/P2) are derived from ChIP-on-Chip data and predicted gene activation (≥1.8). Relative gene
expression was then examined by real time PCR (Taqman) comparing P25 and P2 normal retina. Gene expression was also
compared between normal retinas (P33) and Rd1 retinas (P33) that had lost >99.7% of their rod-photoreceptors. † p<0.001, t-
test. LCA9 (recessive Leber congenital amaurosis, Type 9); MCDR3 (dominant macular dystrophy-3); MDDC, CYMD
(dominant macular dystrophy cystoid); CORD4 (cone rod dystrophy) ‡ location by estimation, not yet mapped.
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265retinal  function.  Many  of  the  genes  also  have  human
homologs located within the mapped intervals of currently
unidentified human retinal diseases, which we continue to
explore. Unlike many genes in embryonic stem cells, genes
activated during terminal maturation of photoreceptors did not
appear to be preloaded with inactive Pol-II. High-resolution
mapping of Pol-II association can also reveal gene-specific
promoter  activation  mechanisms.  One  example  is  the
involvement of the upstream enhancer region in the activated
Rho  promoter  complex.  Genome-wide  maps  of  Pol-II
association  around  TSSs  in  a  mammalian  retina  (mouse)
provide a new resource for correlation to expression data.
These  maps  are  also  viewable  in  the  UCSC  Genome
Browser and EyeBrowse as a shared resource.
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270Appendix 1. Supplemental Genome Browser Guide.
To access the data, click or select the words “Appendix
1.” This will initiate the download of a (pdf) archive that
contains the file.
Appendix 2. Genes predicted to experience most of their activation after
P-2.
To access the data, click or select the words “Appendix
2.” This will initiate the download of a (pdf) archive that
contains the file.
Appendix 3. Genes activated after P2, with Pol-II peak signal ratios ≥ 1.8,
that recruit FIZ1.
To access the data, click or select the words “Appendix
3.” This will initiate the download of a (pdf) archive that
contains the file.
Appendix 4. Novel gene activation increases predicted by Pol-II ChIP-on-
Chip
Genes.  To  access  the  data,  click  or  select  the  words
“Appendix  4.”  This  will  initiate  the  download  of  a  (pdf)
archive that contains the file.
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